Is aspirin still recommended for primary prevention?

The USPSTF recommends against initiating low-dose aspirin use for the primary prevention of CVD in adults 60 years or older.

When do you add aspirin for primary prevention?

The 2022 USPSTF recommendations6-8 suggest that the decision to initiate low-dose aspirin for the primary prevention of CVD in adults ages 40 to 59 years who have a 10% or greater 10-year CVD risk should be an individual one (C statement), and recommends against initiating low-dose aspirin use for the primary …

Why is aspirin not used in primary prevention?

UK and EU guidelines also do not recommend aspirin for primary prevention of cardiovascular disease because of the increased risk of major bleeding.

What are the new aspirin guidelines?

The U.S. Preventive Services Task Force (USPSTF) recently finalized new recommendations for using low-dose aspirin as a means of broadly preventing heart disease and its life-threatening complications, advising against initiating daily aspirin in adults 60 years or older, in particular.

Is aspirin still recommended for stroke prevention?

April 27, 2022 – People who are age 60 or older should not begin taking daily aspirin to prevent a first heart attack or stroke, according to new recommendations from the U.S. Preventive Services Task Force.

What is the latest news on taking aspirin?

The US Preventive Service Task Force has finalized its latest recommendations on low-dose aspirin regimens and now says people over 60 should not start taking a daily aspirin for primary prevention of heart problems, in most cases.

What should be assessed before administering aspirin?

Assess patient for signs of bleeding (petechiae, ecchymosis, bloody or black stools, bleeding gums). Drink adequate fluids while taking aspirin. Advise patient to avoid alcohol when prescribed high doses of aspirin. Baby aspirin is preferred for acute or prophylactic management of heart disease.

What are the USPSTF guidelines for aspirin use to prevent CVD?

The USPSTF recommends initiating low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years (grade B recommendation).

When should primary prevention aspirin be used in patients aged 50-59?

Several guidelines and guidance documents, including the 2016 USPSTF, recommended use of primary prevention aspirin for patients aged 50-59 years at elevated CVD risk without bleeding (Grade B).

Is aspirin effective for primary prevention?

In 2018, three key trials of primary prevention with aspirin were published. First, the ASPREE trial found that among healthy older patients (aged ≥65 years), use of low-dose daily aspirin was associated with increased risk for mortality (5.9% vs. 5.2% for placebo at median 4.7 years) and cancer mortality (3.1% vs. 2.3%).

Is there a benefit-risk trade-off in aspirin use for primary prevention?

This adverse benefit-risk trade-off is reflected in recent trends indicating a reduction in the use of aspirin for primary prevention in the United States.33 Another consideration which should guide aspirin use for primary prevention is patient preference.